Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		103 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (14,978,879)	$ (4,221,184)	$ (41,560,070)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	34,331	13,712	63,793
Interest accrued on promissory note	0	1,264	0
Change in fair value of warrant liability	(5,018,224)	1,517,583	(4,404,209)
Financing expense	368,524	0	368,524
Stock-based compensation	382,611	958,121	8,540,460
Common stock issued for services	0	0	98,703
Common stock issued for research and development	0	0	1,335,760
Changes in assets and liabilities:
Other assets	(501,714)	(240,585)	(670,583)
Accounts payable	91,421	77,636	1,225,012
Accrued liabilities	397,899	329,557	842,648
Net cash used in operating activities	(9,187,583)	(4,599,062)	(25,351,544)
Cash flows from investing activities:
Purchase of property and equipment	(5,668)	(65,108)	(151,532)
Cash paid for sale of Optical Molecular Imaging, Inc.	0	0	(25,000)
Net cash used in investing activities	(5,668)	(65,108)	(176,532)
Cash flows from financing activities:
Proceeds from exercise of stock options	20,500	382,680	450,713
Proceeds from exercise of warrants	3,153,852	0	3,616,600
Payments on promissory note receivable	0	53,018	53,018
Proceeds from issuance of common stock and warrants net of offering costs	9,371,370	7,460,129	27,508,979
Proceeds from issuance of preferred stock and warrants, net of offering costs	0	0	3,779,158
Proceeds from issuance of common stock	0	0	125,247
Net cash provided by financing activities	12,545,722	7,895,827	35,533,715
Increase in cash and cash equivalents	3,352,471	3,231,657	10,005,639
Cash and cash equivalents, beginning of period	6,653,168	5,319,776	0
Cash and cash equivalents, end of period	10,005,639	8,551,433	10,005,639
Supplemental cash flows disclosures:
Interest expense paid	0	0	0
Income taxes paid	0	0	0
Supplemental non-cash financing disclosures:
Exercise of warrants in exchange for promissory note	0	0	3,350,000
Redemption of preferred stock for repayment of promissory note	0	0	3,350,000
Deemed dividend on redemption of preferred stock	0	0	2,092,500
Warrant liability converted to additional paid-in capital	1,944,688	0	1,944,688
Deposits used to acquire property and equipment	$ 35,882	$ 0	$ 35,882